We would love to hear your thoughts about our site and services, please take our survey here.
So has the BOD. They have decided that SRA737 has no value but not willing to take some consequence. It might be worth 2£M plus and could habe helped to finance 2024. Instead share dilution and possibly interest to pay was best BOD could bring up on the table.
Rand over.
Hoping for an answer on my questionaire:
i) With reference to your Final Results for the year ended June, 30 2023 the comment in No 13 states that the leasing arrangement on the office occupied by the company expires in December 2023. Do you abandon the location and settle somewhere else? What time do you move and where to?
ii)
Please detail how many GBP the company spent to its Financial Broker and Advisers, i.e Peel Hunt LLP, Hybridan LLP etc., in fiscal year 2021 and 2022.
iii)
The investment by the Group with CPF to advance the SRA737 programme has a Net book value of GBP 23,000 only. Please explain why the interest in CPF or the associate has been impaired in total by 96% at June, 30 2023.
iv) Administrative expenses total BGP 4,048,000. Please indicate what amount on research and development expenses were recognised as incurred in connection with outsourced and preclinical studies? Please outline for the year endet June 30, 2023 and the prior year.
With reference to your Final Results for the year ended June, 30 2023 the comment in No 13 states that the leasing arrangement on the office occupied by the company expires in December 2023. Do you abandon the location and settle somewhere else? What time do you move and where to?
Well spoken attendee. Mismanagement, no marketing and compounds are like a death horse because of mismanagement. Parker takes that point. Bur will he change communication from now on?
I still wonder if a big Pharma was interested in buying 27.5 % interest of SRA737 meanwhile and if any request and offer was senied.
£20k was very cheap and a bargain. That is what an external professional adviser can earn a month.
If not mistaken, I think it was Peel Hint who advised the equity split. They may have supervised it also. $$$
Spot on Potnak @15:40. Financing is crucial and reality.
Plan D may come into effect which should have already by end of June. If our partial interest in 737 shall be worth something BOD go figure out how much it is and bring it on for sale. SRA737 and its movement is beyond our control thus worthless in a way, isn't it?
This sounds like a good deal to me and was a possible route for SAR also, hopefully in a not to distant future.
Sorry if already posted.
https://www.investing.com/news/assorted/avidity-biosciences-inc-announces-expansion-of-cardiovascular-collaboration-with-bristol-myers-squibb-432SI-3244667
Any assumptions what our 27.5% SRA737 is worth, if it was for sale? I assume there are interested parties around.
Many thanks.
Going forward it is obvious that in a years time company remain broken as we are right now. Any further action like setting up a distribution chain for the capsule or progressing 1802 is costly next to providing 0.5M£ yearly on salaries.
BOD prioritise!
SRA 737 must go unless it is long term strategy to provide it all to a 3rdP when we go bust eventually because no further funding shall be available. That is great risk for us LTH and out of our hands.
Something to stress on at the AGM. If a native speaker was so kind.
Rose tinted glasses put off for the time being given the BS facts and decisions made.
Have a good day all.
Tim & Co have enough you presume they don't get overexcited or greedy?
How much did they actually have on opportunity costs so far, I' wondering.